Myrelez (Lanreotide Acetate)

Lanreotide acetate, the active ingredient in Myrelez, is a somatostatin analog presented as a sterile aqueous solution for subcutaneous injection. It is used to control excess growth hormone in patients with acromegaly and to manage hormone‑secreting neuroendocrine tumors. GNH USA supplies Myrelez as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Myrelez, a somatostatin analog, is employed in conditions driven by excess hormone secretion. - Acromegaly: reduces growth hormone levels and can shrink pituitary adenomas. - Gastroenteropancreatic neuroendocrine tumors: controls hormone‑related symptoms and slows tumor progression. - Carcinoid syndrome: alleviates flushing, diarrhea and other secretory symptoms.

Adverse reactions may occur with lanreotide therapy.

Common Side Effects: - Injection site pain or erythema - Diarrhea - Nausea - Abdominal pain or discomfort - Constipation - Headache

Serious or Rare Side Effects: - Gallstone formation or biliary colic - Hyperglycemia or new‑onset diabetes mellitus - Acute pancreatitis - Severe allergic reactions (anaphylaxis, angioedema) - Significant injection‑site necrosis or infection

Patients should be monitored for specific safety considerations before and during treatment. - Glucose monitoring: assess blood sugar levels, especially in diabetic patients. - Gallbladder assessment: evaluate for gallstones or biliary disease prior to initiation. - Hypersensitivity: check for known allergy to lanreotide or formulation components. - Dose adjustment: consider renal or hepatic impairment when determining dosing. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk, as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide may interact with other medications, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concomitant use with other somatostatin analogues (e.g., octreotide) due to additive hormonal suppression. - Co‑administration with insulin or oral hypoglycemics may cause severe hypoglycemia; dose adjustments are required.

Moderate Interactions (Monitor Closely): - Drugs that affect gastrointestinal motility (e.g., anticholinergics) may exacerbate constipation. - CYP450 substrates metabolized by the liver may have altered plasma levels; monitor therapeutic response. - Vaccines: live attenuated vaccines may have reduced efficacy; schedule vaccination appropriately.